12:00 AM
Dec 24, 2001
 |  BioCentury  |  Strategy

Investing in the sales channel

A major reason biotech companies partner with pharma is to obtain access to large sales organizations that can address primary care and other broad markets. Alkermes Inc. may have found a different entrée to such markets by acquiring a minority stake in Reliant Pharmaceuticals LLC, a marketing company seeking to play in the size gap between big pharma and specialty pharmaceutical companies.

ALKS (Cambridge, Mass.) hopes last week's deal will help it move its own focus away from partners' products and toward commercializing its own.

ALKS paid $100 million in cash - about a third of its $295.4 million in cash at Sept. 30 - for a 19% stake in Reliant...

Read the full 545 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >